234 related articles for article (PubMed ID: 32983280)
1. An Elucidative Review to Analytically Sieve the Viability of Nanomedicine Market.
Kad A; Pundir A; Arya SK; Bhardwaj N; Khatri M
J Pharm Innov; 2022; 17(1):249-265. PubMed ID: 32983280
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicines accessible in the market for clinical interventions.
Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
[TBL] [Abstract][Full Text] [Related]
3. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities.
Agrahari V; Agrahari V
Drug Discov Today; 2018 May; 23(5):974-991. PubMed ID: 29406263
[TBL] [Abstract][Full Text] [Related]
4. Current status and vision of local pharmaceutical industries in Saudi Arabia: The focus on nanomedicines.
Halwani AA; Balkhi B; Alamoudi AA; Almozain NH; Alajmi AM; Noorwali A; Badr MY; Noor AO; Bagalagel A; Tawfik EA
Saudi Pharm J; 2023 Aug; 31(8):101674. PubMed ID: 37448843
[TBL] [Abstract][Full Text] [Related]
5. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
Hock SC; Ying YM; Wah CL
PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
[TBL] [Abstract][Full Text] [Related]
6. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.
Farjadian F; Ghasemi A; Gohari O; Roointan A; Karimi M; Hamblin MR
Nanomedicine (Lond); 2019 Jan; 14(1):93-126. PubMed ID: 30451076
[TBL] [Abstract][Full Text] [Related]
7. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
Halwani AA
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
[TBL] [Abstract][Full Text] [Related]
8. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
[TBL] [Abstract][Full Text] [Related]
9. Challenges associated and approaches for successful translation of nanomedicines into commercial products.
Agrahari V; Hiremath P
Nanomedicine (Lond); 2017 Apr; 12(8):819-823. PubMed ID: 28338401
[No Abstract] [Full Text] [Related]
10. Nanomedicines as cancer therapeutics: current status.
Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
[TBL] [Abstract][Full Text] [Related]
11. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up.
Operti MC; Bernhardt A; Grimm S; Engel A; Figdor CG; Tagit O
Int J Pharm; 2021 Aug; 605():120807. PubMed ID: 34144133
[TBL] [Abstract][Full Text] [Related]
12. Robotics and Aseptic Processing in View of Regulatory Requirements.
Tanzini A; Ruggeri M; Bianchi E; Valentino C; Vigani B; Ferrari F; Rossi S; Giberti H; Sandri G
Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376030
[TBL] [Abstract][Full Text] [Related]
13. The nanomedicines alliance: an industry perspective on nanomedicines.
Malinoski FJ
Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
[TBL] [Abstract][Full Text] [Related]
14. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
[TBL] [Abstract][Full Text] [Related]
15. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
[TBL] [Abstract][Full Text] [Related]
16. Regulatory aspects on nanomedicines.
Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
[TBL] [Abstract][Full Text] [Related]
17. Are existing standard methods suitable for the evaluation of nanomedicines: some case studies.
Gioria S; Caputo F; Urbán P; Maguire CM; Bremer-Hoffmann S; Prina-Mello A; Calzolai L; Mehn D
Nanomedicine (Lond); 2018 Mar; 13(5):539-554. PubMed ID: 29381129
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.
Ragelle H; Danhier F; Préat V; Langer R; Anderson DG
Expert Opin Drug Deliv; 2017 Jul; 14(7):851-864. PubMed ID: 27730820
[TBL] [Abstract][Full Text] [Related]
19. Clinical translation of nanomedicines: Challenges, opportunities, and keys.
Younis MA; Tawfeek HM; Abdellatif AAH; Abdel-Aleem JA; Harashima H
Adv Drug Deliv Rev; 2022 Feb; 181():114083. PubMed ID: 34929251
[TBL] [Abstract][Full Text] [Related]
20. Nanopharmaceuticals (part 2): products in the pipeline.
Weissig V; Guzman-Villanueva D
Int J Nanomedicine; 2015; 10():1245-57. PubMed ID: 25709446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
